How big of an opportunity does Veeva have?

1. The Big Drivers Moving
Veeva Forward

2. A Quick Primer
• Veeva was founded by Peter
Gassner, a former Salesforce
(NYSE: CRM) executive, who
saw a cloud need in pharma.
• Veeva’s platform is still hosted
on salesforce.com.
• Through three different
platforms—CRM, Vault, and
Network—Veeva helps manage
data.

3. The Industry is Outdated
 E-mail is used by 69% of
study sponsors for
communication with contract
research organizations
(CROs).
 Paper shipments are used by
57% of these partners for
communication.
 These are both difficult to
organize and unsecured
when compared to cloud
solutions.

4. Businesses Think Using Veeva-
Type Systems is Advantageous
 56% of eTMF (Veeva-like)
users do so for cost savings.
 55% do so to speed up the
start of studies.
 49% do so to improve the
monitoring of studies.
 45% believe that using eTMF
systems increase readiness
for regulatory inspection.

5. Those Who Have Already
Adopted eTMF Are Happy
The results were a little surprising, in that the most
advantageous benefits of using eTMF systems didn’t
meet up with the perceived benefits perfectly.
 68% of eTMF respondents said the systems helped
track and view documents in real-time.
 65% said that it was easier to search for and find
relevant documents.
 Tracking execution and design metrics for clinical trials
vastly improved document quality, audit readiness,
collaboration, and compliance.

6. But, Hardly Anyone is Using eTMFs
 13% of trial sponsors only use paper-based tracking.
 26% use internal file sharing systems.
 18% use publicly available cloud-sharing systems.
 30% use content management systems.
 Only 13% use dedicated eTMF applications like Veeva Vault.

7. What this Means for
Investors…
 Some may be skeptical of the findings, as the study
was carried out by Veeva and paints a picture of a
huge market opportunity.
 That being said, there’s little doubt that the companies
providing the most value for streamlining clinical trials
will win the most contracts over the coming years.
 Veeva’s stock will likely continue to be volatile, and is
still priced for heavy growth, trading at 86 times
expected 2014 earnings.

8. More Than One Way to Make
Money in Healthcare
While Veeva represents a potentially lucrative business in
healthcare, there are other options, like this one
highlighted in the Motley Fool’s special free report:
A Blockbuster to Make Every
Healthcare Company Jealous